Comparative Pharmacology
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus NORLUTATE.
MEDROXYPROGESTERONE ACETATE vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that binds to progesterone receptors, inhibiting gonadotropin secretion (LH, FSH) from the pituitary, thereby suppressing ovulation and altering the endometrial lining.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
150 mg IM every 3 months for contraception; 400-1000 mg IM weekly for endometrial cancer; 5-10 mg PO daily for secondary amenorrhea.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 12-17 hours after oral administration; with depot intramuscular injection, the half-life is prolonged (up to 50-60 days due to slow release from injection site).
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Deslanoside
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMedroxyprogesterone acetate + Acetyldigitoxin
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Primarily metabolized in the liver; metabolites are excreted in urine (50-70%) and feces (30-50%). Less than 5% excreted unchanged in urine.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Acetyldigitoxin."